Citations

Clear

2429 citation(s) found for "Shah, SS".

Contemporary Trends in Nephrectomy for Renal Cell Carcinoma in the United States: Results From a Population Based Cohort
Kim, Simon P. , Shah, Nilay D. , Weight, Christopher , Thompson, R. Houston, Moriarty, James P. , Shippee, Nathan D. , Costello, Brian A. , Boorjian, Stephen A. , Leibovich, Bradley C. , Shippee, Nathan

Mayo Clinic

Journal of Urology | September 26, 2011 | Volume: 186 | Issue: 5 | Pages: 1779-1785

10.1016/j.juro.2011.07.041 | PMID 21944105 Get It

Optimization of PSA Screening Policies
Balasubramanian, Hari , Shah, Nilay D., Inman, Brant A. , Zhang, Jingyu , Denton, Brian T. , Inman, Brant A

Mayo Clinic

Medical Decision Making | September 20, 2011 | Volume: 32 | Issue: 2 | Pages: 337-349

10.1177/0272989x11416513 | PMID 21933990 Get It

Objective. To estimate the benefit of PSA-based screening for prostate cancer from the patient and societal perspectives. Method. A partially observable Markov decision process model was used to optimize PSA screening decisions. Age-specific prostate cancer incidence rates and the mortality rates from prostate cancer and competing causes were considered. The model trades off the potential benefit of early detection with the cost of screening and loss of patient quality of life due to screening and treatment. PSA testing and biopsy decisions are made based on the patient’s probability of having prostate cancer. Probabilities are inferred based on the patient’s complete PSA history using Bayesian updating. Data Sources. The results of all PSA tests and biopsies done in Olmsted County, Minnesota, from 1993 to 2005 (11,872 men and 50,589 PSA test results). Outcome Measures. Patients’ perspective: to maximize expected quality-adjusted life years (QALYs); societal perspective: to maximize the expected monetary value based on societal willingness to pay for QALYs and the cost of PSA testing, prostate biopsies, and treatment. Results. From the patient perspective, the optimal policy recommends stopping PSA testing and biopsy at age 76. From the societal perspective, the stopping age is 71. The expected incremental benefit of optimal screening over the traditional guideline of annual PSA screening with threshold 4.0 ng/mL for biopsy is estimated to be 0.165 QALYs per person from the patient perspective and 0.161 QALYs per person from the societal perspective. PSA screening based on traditional guidelines is found to be worse than no screening at all. Conclusions. PSA testing done with traditional guidelines underperforms and therefore underestimates the potential benefit of screening. Optimal screening guidelines differ significantly depending on the perspective of the decision maker.
Quality Adjustment for Health Care Spending on Chronic Disease: Evidence from Diabetes Treatment, 1999–2009
Eggleston, Karen , Shah, Nilay D., Smith, Steven A., Berndt, Ernst R. , Newhouse, Joseph P.

Mayo Clinic

American Economic Review | June 1, 2011 | Volume: 101 | Issue: 3 | Pages: 206-211

10.1257/aer.101.3.206 | PMID 29517880 Get It

Although US health care expenditures reached 17.6 percent of GDP in 2009, quality measurement in this important service sector remains limited. Studying quality changes associated with 11 years of health care for patients with diabetes, we find that the value of reduced mortality and avoided treatment spending, net of the increase in annual spending, was $9,094 for the average patient. These results suggest that the unit cost of diabetes treatment, adjusting for the value of health outcomes, has been roughly constant. Since input prices have not been declining, our results are consistent with productivity improvement in health care.
Impact of New Drugs and Biologics on Colorectal Cancer Treatment and Costs
Karaca‐Mandic, Pinar , McCullough, Jeffrey S. , Siddiqui, Mustaqeem , Houten, Holly Van, Shah, Nilay D., Siddiqui, Mustaqeem A

Mayo Clinic

Journal of Oncology Practice | May 18, 2011 | Volume: 7 | Issue: 3S | Pages: e30s-e37s

10.1200/jop.2011.000302 | PMID 21886509 Get It

We measured the financial consequences of new CRC treatment regimens. New regimens have increased cost directly through price and indirectly through nonstandard and second-line regimen use.
Personalizing Evidence-Based Primary Prevention With Aspirin
Kent, David M. , Shah, Nilay D. , Kent, David M

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | May 17, 2011 | Volume: 4 | Issue: 3 | Pages: 260-262

10.1161/circoutcomes.111.961136 | PMID 21586722 Get It

Optimizing Statin Treatment Decisions for Diabetes Patients in the Presence of Uncertain Future Adherence
Mason, Jennifer, England, Darin, Denton, Brian T., Smith, Steven A., Kurt, Murat , Shah, Nilay D., Denton, Brian T.

Mayo Clinic

Medical Decision Making | April 29, 2011 | Volume: 32 | Issue: 1 | Pages: 154-166

10.1177/0272989x11404076 | PMID 21531901 Get It

Background. Statins are an important part of the treatment plan for patients with type 2 diabetes. However, patients who are prescribed statins often take less than the prescribed amount or stop taking the drug altogether. This suboptimal adherence may decrease the benefit of statin initiation. Objective. To estimate the influence of adherence on the optimal timing of statin initiation for patients with type 2 diabetes. Method. The authors use a Markov decision process (MDP) model to optimize the treatment decision for patients with type 2 diabetes. Their model incorporates a Markov model linking adherence to treatment effectiveness and long-term health outcomes. They determine the optimal time of statin initiation that minimizes expected costs and maximizes expected quality-adjusted life years (QALYs). Results. In the long run, approximately 25% of patients remain highly adherent to statins. Based on the MDP model, generic statins lower costs in men and result in a small increase in costs in women relative to no treatment. Patients are able to noticeably increase their expected QALYs by 0.5 to 2 years depending on the level of adherence. Conclusions. Adherence-improving interventions can increase expected QALYs by as much as 1.5 years. Given suboptimal adherence to statins, it is optimal to delay the start time for statins; however, changing the start time alone does not lead to significant changes in costs or QALYs.
Projecting future drug expenditures—2011
Doloresco, Fred, Fominaya, Cory E. , Schumock, Glen T., Vermeulen, Lee C. , Matusiak, Linda M., Hunkler, Robert J., Shah, Nilay D., Hoffman, James M.

Mayo Clinic

American Journal of Health-System Pharmacy | April 7, 2011 | Volume: 68 | Issue: 10 | Pages: 921-932

10.2146/ajhp100712 | PMID 21546644 Get It

Protein kinase G signaling disrupts Rac1-dependent focal adhesion assembly in liver specific pericytes
Routray, Chittaranjan, Liu, Chunsheng , Yaqoob, Usman , Billadeau, Daniel D. , Bloch, Kenneth D., Kaibuchi, Kozo , Shah, Vijay H. , Kang, Ningling , Yaqoob, Usman

Mayo Clinic

American Journal of Physiology-Cell Physiology | March 31, 2011 | Volume: 301 | Issue: 1 | Pages: C66-C74

10.1152/ajpcell.00038.2011 | PMID 21451103 Get It

Nitric oxide (NO) regulates the function of perivascular cells (pericytes), including hepatic stellate cells (HSC), mainly by activating cGMP and cGMP-dependent kinase (PKG) via NO/cGMP paracrine signaling. Although PKG is implicated in integrin-mediated cell adhesion to extracellular matrix, whether or how PKG signaling regulates the assembly of focal adhesion complexes (FA) and migration of HSC is not known. With the help of complementary molecular and cell biological approaches, we demonstrate here that activation of PKG signaling in HSC inhibits vascular tubulogenesis, migration/chemotaxis, and assembly of mature FA plaques, as assessed by vascular tubulogenesis assays and immunofluorescence localization of FA markers such as vinculin and vasodilator-stimulated phosphoprotein (VASP). To determine whether PKG inhibits FA assembly by phosphorylation of VASP at Ser-157, Ser-239, and Thr-278, we mutated these putative phosphorylation sites to alanine (VASP3A, phosphoresistant mutant) or aspartic acid (VASP3D, phosphomimetic), respectively. Data generated from these two mutants suggest that the effect of PKG on FA is independent of these three phosphorylation sites. In contrast, activation of PKG inhibits the activity of small GTPase Rac1 and its association with the effector protein IQGAP1. Moreover, PKG activation inhibits the formation of a trimeric protein complex containing Rac1, IQGAP1, and VASP. Finally, we found that expression of a constitutively active Rac1 mutant abolishes the inhibitory effects of PKG on FA formation. In summary, our data suggest that activation of PKG signaling in pericytes inhibits FA formation by inhibiting Rac1.
Assessment of Chronic Hepatitis and Fibrosis: Comparison of MR Elastography and Diffusion-Weighted Imaging
Wang, Yi , Ganger, Daniel , Levitsky, Josh , Sternick, Laura A., McCarthy, Robert J. , Chen, Zongming E., Fasanati, Charles, Bolster, Bradley D. , Shah, Saurabh , Zuehlsdorff, Sven , Omary, Reed A. , Miller, Frank H. , Ehman, Richard L. , Miller, Frank H

Mayo Clinic

American Journal of Roentgenology | February 22, 2011 | Volume: 196 | Issue: 3 | Pages: 553-561

10.2214/ajr.10.4580 | PMID 21343496 Get It

Left Ventricular Assist Device Therapy in Patients With Restrictive and Hypertrophic Cardiomyopathy
Topilsky, Yan , Pereira, Naveen L. , Shah, Dipesh K. , Boilson, Barry A. , Schirger, John A., Kushwaha, Sudhir S. , Joyce, Lyle D., Park, Soon J., Topilsky, Yan , Topilsky, Yan

Mayo Clinic

Circulation: Heart Failure | February 9, 2011 | Volume: 4 | Issue: 3 | Pages: 266-275

10.1161/circheartfailure.110.959288 | PMID 21303989 Get It

Background— Left ventricular assist device (LVAD) is being increasingly used in patients with end-stage dilated and ischemic cardiomyopathy. There have been no clinical trials addressing the use of LVAD therapy in patients with end-stage heart failure caused by restrictive (RCM) or hypertrophic cardiomyopathy (HCM). The purpose of this study was therefore to analyze the outcome of LVAD therapy in these patients. Methods and Results— Eighty-three patients received continuous axial flow LVAD (Heart mate II, Thoratec, Pleasanton, CA) from February 2007 to May 2010 at our institution. We analyzed the baseline characteristics and surgical and long-term impact of LVAD therapy in 8 patients with RCM or HCM and compared their outcomes with the 75 patients with dilated and ischemic cardiomyopathy. Compared with patients with ischemic or dilated cardiomyopathy, patients with RCM and HCM have significantly smaller left ventricular end-diastolic dimensions (52.5±6 mm versus 68.6±8 mm; P <0.0001) and increased thickness of septal (16 [12, 19] mm versus 10[8.5, 11] mm, P =0.0003) and higher left ventricular ejection fraction (21 [20, 36]% versus 17 [15, 22]%; P =0.0009). We found no difference in early mortality (12.5% versus 9.3%, P =0.57) or length of hospital stay (11 [8, 45] days versus 18.5 [12.2, 27.7] days; P =0.51) between the 2 groups. The right atrial pressure was higher (18 [15, 20] mm Hg versus 12 [9, 15] mm Hg, P =0.03), and pump flow was lower (4.3 [3.8, 4.5] L versus 5.2 [4.7, 5.5] L, P =0.001) after LVAD implantation in patients with RCM and HCM. Central venous catheter related infections were more common in patients with RCM and HCM (87.5% versus 44.5%, P =0.006). There was no difference in the total number of blood units transfused. Median (min, max) follow-up duration after LVAD implantation was 166 [1, 1044] days. The 1-year actuarial survival rate was not different between the 2 groups (87.5% [95% confidence interval, 52.9% to 97.8%] versus 73.2 [95% confidence interval, 60% to 85%]; P =0.77). Conclusions— Our preliminary data show that patients with end-stage heart failure caused by RCM or HCM may benefit from continuous axial flow LVAD therapy. This small study suggests that mortality is comparable with those patients who have dilated or ischemic cardiomyopathy, but right heart failure, prolonged inotropic use, and central venous catheter infections are more common in patients with RCM and HCM who were treated with LVAD. Because of the small numbers the differences should be interpreted cautiously, and prospective clinical trials would be required to recommend this therapy for these patients as bridge to transplantation or destination treatment.